Santhera cleared for visual impairment treatment Raxone in Israel
Santhera Pharmaceuticals has been cleared in Israel for Raxone (idebenone) for visual impairment in adolescents and older, with Leber’s hereditary optic neuropathy (LHON).
Pharmaceuticals, Biotechnology and Life Sciences
Santhera Pharmaceuticals has been cleared in Israel for Raxone (idebenone) for visual impairment in adolescents and older, with Leber’s hereditary optic neuropathy (LHON).
US Food and Drug Administration (FDA) has approved Novartis’s Kymriah suspension for intravenous infusion, formerly CTL019, the first chimeric antigen…
Stada’s Executive Board presented sound figures for financial year 2016 and a positive outlook for business development in 2017. Board’s…
OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base, said Stephen O’Hara, CEO of OptiBiotix Wednesday in the half year financial report.
Amryt Pharma, a biopharmaceutical company focused on rare and orphan diseases, has appointed Kieran Rooney, as Vice President of Strategic Alliances and Licensing.
Allergan has reached a settlement regarding its litigation with Famy Care Limited relating to certain Allergan’s United States Patent covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.
GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…
Sanofi has acquired USA based Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. The Federal Trade Commission’s approval…
CF PharmTech has raised $65M in a Series D financing with a future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited, led the financing along with other prestigious healthcare investment groups in China.
Lumosa Herapeutics said Monday that the FDA has confirmed its submission of the NDA of LT1001 Naldebain in the US. Naldebain IM injection has received market authorization and launched in Taiwan as the world’s first 7-day long-acting analgesic injection for moderate to severe post-operative pain.